Two Onc Docs ASCO 2025 Plenary: SERENA-6
Jun 24, 2025
Delve into groundbreaking advancements in breast cancer treatment with discussions on the SERENA-6 trial. The focus is on the promising combination of camisetrant and CDK 4/6 inhibitors for advanced hormone receptor-positive cases. Highlights include impressive progression-free survival improvements and the innovative use of circulating tumor DNA in managing patient care. Concerns about safety profiles and how these findings integrate into current practices add depth to the conversation.
AI Snips
Chapters
Transcript
Episode notes
ESR1 Mutation Drives Resistance
- ESR1 mutations cause estrogen receptor activation independent of estrogen, driving resistance in HR+ HER2- breast cancer.
- Camizestrant is a next-generation selective estrogen receptor degrader designed to inhibit and degrade these mutations.
Early ctDNA Detection Guides Therapy
- SERENA-6 uses ctDNA monitoring to detect emergent ESR1 mutations early during first-line therapy.
- Patients with detected ESR1 mutations are randomized to switch to camizestrant plus CDK4-6i or continue AI plus CDK4-6i.
Camizestrant Improves PFS and QoL
- Switching to camizestrant upon ESR1 mutation detection significantly prolonged PFS from 9.2 to 16 months.
- Patient-reported outcomes showed better quality of life and longer time to deterioration with camizestrant.